Analogous products animal models

Inhibitors of MLK (MKKK) [27], MKK4, 7 and JNK [6,28,29] have been disclosed to date. CEP-1347, a semi-synthetic analog of the natural product K252a, inhibits MLKs in the JNK pathway with K = 17 nM [30-32]. This compound has shown neuroprotective effects in cellular and animal models [33]. CEP-1347, an orally available compound that was well tolerated in the clinic, was advanced to Phase II/III trials for assessing efficacy in Parkinson s disease. However, the clinical trial was stopped due to a lack of significant efficacy [34],... 

As is true for all biopharmaceuticals, toxicity studies should be performed in relevant animal models. For cellular therapies these models are often in animal models intended to mimic the human disease. When possible the intended human cells are utilized for assessments with or without low-dose immunosuppressants (e.g., lOmg/kg, i.p. dose of cyclosporine A in rats). The immunosuppressive drug is generally administered prior to the cell dose and extended for a specified period after the transplant. In cases where it is not feasible to use the intended clinical material, largely due to the inability of the cells to engraft sufficiently into the host, analogous cells can be used to assess preclinical safety and activity. In such cases it is important to understand the potential impact of any differences between the analogous product and the clinical product in order to improve extrapolation of safe and active cell doses to humans. 

As a result of these unique delivery routes, there is an increased potential for toxicity to tissues at or near the injection site. Assessment of local tolerance and tissue compatibility of the clinical formulation is usually evaluated as part of the animal model of efficacy and/or general toxicity study, thus obviating the need for separate local tolerance studies. There may be additional concerns in cases where analogous products are used including potential differences in formulation, stability, and so forth. 

An ancient one is the production of soap from animal fat. To set that scene, 1 shall consider a simple model system, the hydrolysis (severing apart by water) of the two components of an ester, i (the same compound I used in Reaction 17, a combination of acetic acid and ethanol), and then turn to soapmaking itself You saw in Reaction 17 how esters can be broken down into their components, a carboxylic acid and an alcohol, by an acid here we see the analogous reaction in the presence of a base. To be specific, the reagent is a solution of sodium hydroxide, which provides the OH ions that catalyse the reaction. 

---